Good morning :)
$
₹
Eton Pharmaceuticals Inc

Eton Pharmaceuticals Inc

ETON

NASDAQ
Asset Logo

Eton Pharmaceuticals Inc

ETON

NASDAQ
$50.551.11% (+0.55)
$
₹
$50.551.11% (+0.55)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Small Cap

With a market cap of $1.4B the stock is ranked 2466

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

125
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

22.16
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.4
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

12.02%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 4 analysts reports

Buy
4 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+43%

Earnings Growth

+1900%

Rev. Growth

+87.26%

See Detailed Forecast

Company Profile

Company Profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 43.00% growth, versus a trailing 3-year CAGR of 134.65%.

2026
Current$50Baseline
Analyst Target - 1 year
Target$71.5+43%

All values in $

202220232024202520262027$21.57$40.59$59.62Target+43%
2026
Current$50Baseline
Analyst Target - 1 year
Target$71.5+43%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 87.26% growth, versus a trailing 3-year CAGR of 55.53%.

2025
Current$79.95Baseline
Forecast for Dec 2026
High$152.3+90.49%
Average$149.71+87.26%
Low$147.6+84.62%

All values in $ Million

20212022202320242025202621.8321.2531.6439.0179.95Low+84.62%Average+87.26%High+90.49%
2025
Current$79.95Baseline
Forecast for Dec 2026
High$152.3+90.49%
Average$149.71+87.26%
Low$147.6+84.62%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$0.07Baseline
Forecast for Dec 2026
High$1.52+2071.43%
Average$1.4+1900%
Low$1.28+1728.57%

All values in $

202120222023202420252026-0.11-0.35-0.03-0.150.07Low+1728.57%Average+1900%High+2071.43%
2025
Current$0.07Baseline
Forecast for Dec 2026
High$1.52+2071.43%
Average$1.4+1900%
Low$1.28+1728.57%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

22.4
-1.9
21.2
1.4
24.2
1.5
37.5
11.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue7.969.0710.3211.6417.2818.9222.4521.2824.2637.58
Net Income-0.81-3.040.62-0.59-1.57-2.58-1.921.481.5511.57
Net Profit Margin-10.18%-33.51%6.07%-5.13%-9.09%-13.65%-8.58%6.96%6.40%30.80%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Eton Pharmaceuticals Inc 12522.16-
Eli Lilly and Company42.7430.781.15
Johnson & Johnson40.037.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ETON with any stock or ETF
Compare ETON with any stock or ETF
Comparing from
ETON
LLY
JNJ
Loading...

Frequently asked questions

  1. Eton Pharmaceuticals Inc (ETON) share price today is $50.55 as of October 27, 2026 at 12:13 AM IST. The stock touched a day high of $51.31 and a day low of $49.61.

  2. Eton Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol ETON.

  3. Eton Pharmaceuticals Inc's market capitalization is $1.42B as of October 27, 2026 at 12:13 AM IST.

  4. Eton Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 125 as of October 26, 2026.

  5. Eton Pharmaceuticals Inc's price-to-book (P/B) ratio is 22.16 as of October 26, 2026.

  6. Yes, You can buy Eton Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Eton Pharmaceuticals Inc shares in three steps: 1. Search Eton Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Eton Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Eton Pharmaceuticals Inc (ETON) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1978 shares at the current price of $50.55.

Loading...